Dynamic Advisor Solutions LLC Grows Stock Holdings in Merck & Co., Inc. $MRK

Dynamic Advisor Solutions LLC grew its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 56.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 64,313 shares of the company’s stock after acquiring an additional 23,285 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Merck & Co., Inc. were worth $8,264,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its position in Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after buying an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC boosted its position in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares during the period. Diversify Wealth Management LLC increased its holdings in Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after purchasing an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $128.33 on Thursday. The firm has a market cap of $316.95 billion, a P/E ratio of 102.66, a P/E/G ratio of 5.13 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05. The firm has a fifty day moving average of $123.61 and a two-hundred day moving average of $118.91.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company’s revenue was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 2.72 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue grew 5.1% year over year. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, generating $8.37 billion in quarterly sales, while the injectable formulation substantially exceeded Wall Street expectations. Newer products and pipeline programs also supported the company’s performance. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised its 2026 revenue outlook to $66.3 billion-$67.3 billion, reflecting confidence in Keytruda, newer launches and pipeline progress. Guggenheim also raised its price target to $146 and maintained a Buy rating. MRK Q2 Earnings & Sales Beat Estimates, ’26 Sales View Raised
• Positive Sentiment: Health Canada approved Keytruda combined with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s commercial reach. Health Canada approves Keytruda treatment
• Neutral Sentiment: Merck is accelerating acquisitions and partnerships in hematology, infectious diseases, vaccines, cardiopulmonary medicine and obesity to diversify ahead of Keytruda’s expected U.S. patent-exclusivity loss in 2028. The strategy offers long-term upside but increases execution and spending risks. Merck is racing beyond Keytruda
• Negative Sentiment: Merck lowered its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus, primarily because of acquisition-related charges tied to Terns Pharmaceuticals and other deals. Merck hikes revenue outlook but cuts profit guidance
• Negative Sentiment: Investors remain concerned that Keytruda’s 2028 patent cliff could create a significant revenue gap unless newer products, acquisitions and clinical programs deliver sufficient replacement growth. Merck also reported a mixed development update for anti-TL1A drug tulisokibart, which was discontinued in one rare lung-disease indication. MSD posts a victory and defeat for anti-TL1A

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MRK shares. UBS Group increased their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Citigroup started coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price for the company. Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 8th. Finally, Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Thirteen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $134.56.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.